Skip to Main Content

Paper Details

Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer.
Oncologist
8
2020
FOLFOX, Metastatic Esophagogastric Cancer, PD-1, Patients, Regorafenib, gastroesophageal adenocarcinoma, homologous recombination deficiency, hypertension, leucopenia, leucovorin, metastatic esophagogastric cancer, metastatic gastroesophageal adenocarcinoma, neutropenia, oxaliplatin, patients, platinum, regorafenib, stromal receptor tyrosine kinases, tumors, tyrosine
Author NameAffiliation
Azfar BasuniaMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Azfar BasuniaMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
  • 1 - 17

Datasets

Release 1.2